Amgen Inc. $AMGN Shares Bought by German American Bancorp Inc.

German American Bancorp Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 142.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,304 shares of the medical research company’s stock after buying an additional 2,532 shares during the quarter. German American Bancorp Inc.’s holdings in Amgen were worth $1,514,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the period. State Street Corp lifted its position in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after acquiring an additional 1,287,310 shares during the period. Capital World Investors lifted its position in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the period. Geode Capital Management LLC boosted its stake in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Amgen in the 4th quarter worth approximately $2,164,162,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AMGN shares. The Goldman Sachs Group set a $389.00 price objective on Amgen in a report on Friday, June 5th. Mizuho lifted their price target on Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 16th. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. BMO Capital Markets reissued an “outperform” rating and issued a $400.00 price objective on shares of Amgen in a research note on Wednesday, July 1st. Finally, Truist Financial raised their target price on shares of Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $356.62.

Amgen Trading Down 1.4%

Shares of AMGN stock opened at $366.29 on Friday. The firm has a 50-day moving average price of $347.69 and a 200 day moving average price of $350.38. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29. The company has a market capitalization of $197.69 billion, a price-to-earnings ratio of 25.49, a PEG ratio of 3.76 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts forecast that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen advanced its obesity pipeline with fresh Phase 1 data on AMG 133 injection formats, which could support long-term growth if the program continues to show promise. Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
• Positive Sentiment: Amgen’s stock was highlighted in market coverage as teasing a buy point, suggesting technical traders may see room for upside if broader market conditions stabilize. Stock Market Today: Dow Sees Red While Amgen Shares Tease A Buy Point (Live Coverage)
• Neutral Sentiment: Amgen remains a candidate for another earnings beat, according to recent coverage pointing to its history of topping estimates and solid fundamentals. Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Erste Group slightly lowered its FY2027 EPS estimate for Amgen to $23.58 from $23.62 and kept a Hold rating, a modest negative for sentiment but not a major change in the outlook. Amgen Inc. (NASDAQ:AMGN) Free Report
• Negative Sentiment: Amgen halted a late-stage bemarituzumab gastric cancer trial, adding uncertainty to part of its oncology pipeline and pressuring investor expectations. Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations
• Negative Sentiment: Amgen also terminated a key Phase 3 rocatinlimab eczema study, another setback that may raise concerns about the durability of its pipeline growth. Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.